PMCF_HYAPROF: Safety and Efficacy of the HA-based Dermal Fillers HYAPROF® SOFT and HYAPROF® BALANCE

Sponsor
BioSCIENCE GmbH (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT04546152
Collaborator
HeiMed (Other)
132
2
22.4
66
2.9

Study Details

Study Description

Brief Summary

Purpose of this study is the demonstration of safety and efficacy of the dermal fillers HYAPROF® SOFT and HYAPROF® BALANCE for restoration of the facial volume and contour.

Condition or Disease Intervention/Treatment Phase
  • Device: HYAPROF® SOFT and HYAPROF® BALANCE

Detailed Description

This is a prospective, multicenter, observational, open label, two-arm, crossover, PMCF clinical trial for demonstration of the safety and efficacy of the HA-based dermal fillers HYAPROF® SOFT and HYAPROF® BALANCE for restoration of the facial volume and contour. Besides safety aspects, evaluated immediately after the treatment, 4 weeks, 3 and 6 months after the treatment, the performance of the demal fillers are evaluated in the 3 and 6 months follow-up by using GAIS and WSRS.

Study Design

Study Type:
Observational
Anticipated Enrollment :
132 participants
Observational Model:
Case-Crossover
Time Perspective:
Prospective
Official Title:
Prospective Observational Clinical Trial for Safety and Efficacy of HYAPROF® SOFT and HYAPROF® BALANCE
Actual Study Start Date :
Sep 16, 2020
Anticipated Primary Completion Date :
Apr 30, 2022
Anticipated Study Completion Date :
Jul 31, 2022

Arms and Interventions

Arm Intervention/Treatment
HYAPROF® SOFT

HYAPROF® SOFT is indicated for volume replacement (filling of folds), fine to medium folds, lip augmentation, periorbital region.

Device: HYAPROF® SOFT and HYAPROF® BALANCE
Dermal filler injection to different facial areas

HYAPROF® BALANCE

HYAPROF® BALANCE is indicated for volume replacement (filling of folds), deep folds, nasolabial folds, cheek area, glabella folds. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).

Device: HYAPROF® SOFT and HYAPROF® BALANCE
Dermal filler injection to different facial areas

Outcome Measures

Primary Outcome Measures

  1. Global aesthetic improvement 3 months [3 months]

    Global aesthetic improvement assessment acc. to the Global Aesthetic Improvement Scale (GAIS); 3: very much improved, 2: much improved, 1: improved, 0 unchanged, -1: worse

  2. Global aesthetic improvement 6 months [6 months]

    Global aesthetic improvement assessment acc. to the Global Aesthetic Improvement Scale (GAIS); 3: very much improved, 2: much improved, 1: improved, 0 unchanged, -1: worse

  3. Wrinkle severity assessment 3 months [3 months]

    Wrinkle severity assessment acc. to the Wrinkle Severity Rating Scale (WSRS); 1: wrinkles absent, 2: slight wrinkles, 3: moderate wrinkles, 4: severe wrinkles, 5: very severe wrinkles

  4. Wrinkle severity assessment 6 months [6 months]

    Wrinkle severity assessment acc. to the Wrinkle Severity Rating Scale (WSRS); 1: wrinkles absent, 2: slight wrinkles, 3: moderate wrinkles, 4: severe wrinkles, 5: very severe wrinkles

  5. Number of subjects with wrinkle severity improvement 3 months [3 months]

    Number of subjects with at least one scale point improvement in the wrinkle severity assessment (WSRS) with respect to baseline

  6. Number of subjects with wrinkle severity improvement 6 months [6 months]

    Number of subjects with at least one scale point improvement in the wrinkle severity assessment (WSRS) with respect to baseline

Secondary Outcome Measures

  1. Product safety immediately after the treatment [Immediately after the treatment]

    Side effects and adverse event recording; degree of severity: mild, moderate, severe

  2. Product safety 4 weeks [4 weeks]

    Side effects and adverse event recording; degree of severity: mild, moderate, severe; duration of the event

  3. Product safety 3 months [3 months]

    Side effects and adverse event recording; degree of severity: mild, moderate, severe; duration of the event

  4. Product safety 6 months [6 months]

    Side effects and adverse event recording; degree of severity: mild, moderate, severe; duration of the event

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • subjects intended for the treatment with HYAPROF® SOFT and/or BALANCE according to the instructions for use of the product

  • decision for the treatment with HYAPROF® SOFT and/or BALANCE was made before the subject was recruited for the clinical trial

  • subjects signed written informed consent

  • adult subjects at least 18 years old

  • all Fitzpatrick skin types

  • area treated either with HYAPROF® SOFT or HYAPROF® BALANCE - no combination of the products in one treated area

Exclusion Criteria:
  • tendency to hypertrophic and keloid scarring

  • intolerance to gram-positive bacteria

  • prone to active inflammatory or infectious processes

  • suffering from acute or chronic skin diseases

  • undergoing anti-coagulant therapy

  • known allergy to hyaluronic acid

  • suffering from autoimmune diseases

  • multiple allergies

  • pregnancy or lactating women

  • subjects unlikely to cooperate in the clinical investigation or to comply with the treatment or with the clinical investigation visits

Contacts and Locations

Locations

Site City State Country Postal Code
1 BioSCIENCE Investigation Site #01 Bad Honnef Germany
2 BioSCIENCE Investigation Site #02 Kempten Germany

Sponsors and Collaborators

  • BioSCIENCE GmbH
  • HeiMed

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
BioSCIENCE GmbH
ClinicalTrials.gov Identifier:
NCT04546152
Other Study ID Numbers:
  • CIP HYAPROF SOFT and BALANCE
First Posted:
Sep 11, 2020
Last Update Posted:
Mar 17, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by BioSCIENCE GmbH

Study Results

No Results Posted as of Mar 17, 2022